关于我们
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.
- 网站
-
https://nextcure.com/
NextCure, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Beltsville,Maryland
- 类型
- 上市公司
- 领域
- Biotechnology、Cancer Therapy和Drug Development
地点
-
主要
9000 Virginia Manor Rd
200
US,Maryland,Beltsville,20705
NextCure, Inc.员工
-
John Houston
-
Udayan Guha, M.D.,Ph.D.
Physician Scientist | Clinical Development | Medical Oncologist | Chief Medical Officer, NextCure Inc.
-
Thomas O'Neill
Director of Molecular Biology
-
Anne Borgman, M.D.
Seasoned pharmaceutical executive with 20+ years of successful hematology oncology drug development expertise.